Intensity Therapeutics Inc. (NASDAQ:INTS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by on Jul 24th, 2026

Intensity Therapeutics Inc. (NASDAQ:INTS – Get Free Report) has earned a consensus rating of “Moderate Buy” from the four analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $37.50.

Several analysts recently commented on the stock. Freedom Capital upgraded shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th. Wall Street Zen upgraded shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Finally, Weiss Ratings lowered Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, April 24th.

Get Our Latest Stock Analysis on Intensity Therapeutics

Institutional Investors Weigh In On Intensity Therapeutics

Large investors have recently made changes to their positions in the company. Mesirow Financial Investment Management Inc. raised its position in Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after acquiring an additional 51,000 shares in the last quarter. Jane Street Group LLC bought a new stake in Intensity Therapeutics in the fourth quarter worth approximately $26,000. Corient Private Wealth LLC acquired a new position in shares of Intensity Therapeutics during the 4th quarter worth $41,000. State Street Corp increased its stake in shares of Intensity Therapeutics by 839.3% during the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares during the last quarter. Finally, Legacy Advisors LLC bought a new position in shares of Intensity Therapeutics during the 4th quarter valued at $63,000. Institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Stock Performance

Intensity Therapeutics stock opened at $4.43 on Friday. Intensity Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $43.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.86 and a quick ratio of 4.86. The company has a market cap of $11.96 million, a P/E ratio of -0.78 and a beta of 2.78. The firm’s 50 day simple moving average is $4.31 and its 200-day simple moving average is $6.19.

Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.12. As a group, equities research analysts predict that Intensity Therapeutics will post -2.7 EPS for the current year.

About Intensity Therapeutics

(Get Free Report)

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.

Featured Articles

Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.